Article

FDA Warns Health Care Professionals Not to Administer Wallcur IV Solutions

The FDA has alerted health care professionals not to inject human or animal patients with Wallcur, LLC, IV products, which are for training purposes only.

The FDA has alerted health care professionals not to inject human or animal patients with Wallcur, LLC, IV products, which are for training purposes only.

The FDA has been notified that some Wallcur training IV products have been distributed to health care facilities and administered to patients. There have been reports of serious adverse events associated with the use of certain of these products, such as Wallcur’s Practi IV Solution Bags.

Before administering IV solutions to patients, health care providers should carefully check the labels to ensure that the products are not training products. Wallcur’s training products may bear the words “for clinical simulation” and should not be administered to patients.

If you suspect that any Wallcur training IV products may have been administered to a patient, whether or not the incident has resulted in an adverse event, please report the incident to FDA’s MedWatch Adverse Event Reporting program by submitting the form online at www.fda.gov/medwatch/report.htm, downloading it at www.fda.gov/MedWatch/getforms.htm, or calling 1-800-332-1088 to request it. Completed paper forms can be returned to the address on the pre-addressed form or faxed to 1-800-FDA-0178.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit: Sebastian Kaulitzki | stock.adobe.com
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com